CD34 and myeloid neoplasm: Thus, to determine occurrence of FLT3-ITD in distinct phenotypically defined leukemic stem/progenitor subpopulations in relation to pre-leukemic and early leukemic hits, we analyzed ten FLT3-ITD AML samples (five CD34+ and five CD34-, Table 1, patients #1-10) by amplicon based sequencing of 54 genes related to myeloid neoplasms followed by flow cytometric sorting and targeted resequencing of identified alterations within leukemic stem/progenitor subpopulations (Figure 1A, Supplementary Figure 1A and Supplementary Table 1).